Abbvie said Health Canada issued a Notice of Compliance with Conditions for Venclexta

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

ABBVIE said Health Canada has issued a Notice of Compliance with Conditions for Venclexta (venetoclax). The therapy has been approved for previously treated chronic lymphocytic leukemia patients, who have either a genetic mutation, known as 17p deletion, or no other available treatment options. Under NOC/c policy, AbbVie will provide Health Canada with data from additional...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

When Olufunmilayo I. “Funmi” Olopade was born, the most common Nigerian career aspirations were pastor or teacher. Olopade’s father, a pastor, thought differently. He wanted his children to be scientists, economists, and doctors. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login